Namenda Product Hopping Settlement Surpasses Most Recent DOJ Agreements
Executive Summary
Direct purchasers' $750m settlement with Allergan is at least the second involving product hopping claims; only one DOJ settlement surpassed this amount in the past year.
You may also be interested in...
DOJ Casting Wider Net In Pharma Kickback Probes
Government is pursuing behavior it once would have taken a pass on, former DOJ attorney notes; pharma companies have inked 16 settlements in past year.
FTC's First Product Hopping Complaint Targets Safety Claims For Suboxone Film Formulation
Commission files complaint as it reaches $50m settlement with Reckitt Benckiser.
Legal Briefs: Courts On Exclusivity; Namenda ‘Hard Switch’ Deemed Coercive; Acorda Fights Bass Patent Petition
FDA’s active moiety rationale for denying Vascepa five years exclusivity is rejected by district court; Actavis strategy to protect Namenda franchise meets another hurdle; Acorda challenges ‘improper purpose’ of Bass IPR petition.